• Kodiak Sciences posted a first-quarter net loss of $58.2 million, or $0.94 per share, versus a loss of $57.5 million, or $1.09 per share, a year earlier.
• R&D expense climbed to $48.5 million from $43.6 million, driven by higher clinical activity in PEAK/PINNACLE and DAYBREAK studies.
• G&A expense fell to $11.2 million from $15.4 million, helped by sublease income from a corporate office building.
• Cash and cash equivalents totaled $169.5 million, with runway expected into 2027.
• Zenkuda posted positive Phase 3 GLOW2 topline results in diabetic retinopathy, with 62.5% achieving a ≥2-step DRSS improvement versus 3.3% for sham; DAYBREAK Phase 3 topline data in wet AMD expected September 2026, PEAK Phase 3 topline results in MESI expected in 4Q 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605071600PR_NEWS_USPR_____SF54453) on May 07, 2026, and is solely responsible for the information contained therein.